<?xml version='1.0' encoding='UTF-8' standalone='yes'?>
<rss version="2.0">
  <channel>
    <title>Clinical Chemistry and Laboratory Medicine (CCLM)</title>
    <link>www.degruyter.com</link>
    <description/>
    <item>
      <title>Frontmatter</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-frontmatter9/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-frontmatter9/html</guid>
    </item>
    <item>
      <title>EFLM European Urinalysis Guideline</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0078/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0078/html</guid>
    </item>
    <item>
      <title>Clinical Chemistry Laboratory Medicine in the post-acute COVID-19 era</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0756/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0756/html</guid>
    </item>
    <item>
      <title>The EFLM European Urinalysis Guideline 2023</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0070/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0070/html</guid>
    </item>
    <item>
      <title>Approaching sustainability in Laboratory Medicine</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2023-0973/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2023-0973/html</guid>
    </item>
    <item>
      <title>New reimbursement models to promote better patient outcomes and overall value in laboratory medicine and healthcare</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0168/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0168/html</guid>
    </item>
    <item>
      <title>Screening for sickle cell disease: focus on newborn investigations</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0478/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0478/html</guid>
    </item>
    <item>
      <title>The role of Killer immunoglobulin-like receptors (KIRs) in the genetic susceptibility to non-celiac wheat sensitivity (NCWS)</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0034/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0034/html</guid>
    </item>
    <item>
      <title>Understanding the limitations of your assay using EQA data with serum creatinine as an example</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0027/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0027/html</guid>
    </item>
    <item>
      <title>Add-on testing: stability assessment of 63 biochemical analytes in centrifuged and capped samples stored at 16 °C</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2023-1388/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2023-1388/html</guid>
    </item>
    <item>
      <title>Smartphone swabs as an emerging tool for toxicology testing: a proof-of-concept study in a nightclub</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0242/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0242/html</guid>
    </item>
    <item>
      <title>Allergy: Evaluation of 16 years (2007–2022) results of the shared external quality assessment program in Belgium, Finland, Portugal and The Netherlands</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2023-0862/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2023-0862/html</guid>
    </item>
    <item>
      <title>Monoclonal whole IgG impairs both fibrin and thrombin formation: hemostasis and surface plasmon resonance studies</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0252/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0252/html</guid>
    </item>
    <item>
      <title>Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0114/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0114/html</guid>
    </item>
    <item>
      <title>Familial dysalbuminemic hyperthyroxinemia coexisting with a Grave’s disease: a Belgian case report</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0204/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0204/html</guid>
    </item>
    <item>
      <title>Diagnostic challenge between a frequent polygenic hypocholesterolemia and an unusual Smith Lemli Opitz syndrome related to bi-allelic DHCR7 mutations</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0162/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0162/html</guid>
    </item>
    <item>
      <title>First reported co-occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with pseudo Chediak-Higashi anomaly and complex karyotype</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0106/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0106/html</guid>
    </item>
    <item>
      <title>Facing the new IVD Regulation 2017/746: Contract Research Organizations (CROs), key partners of IVDs manufacturers for compliance</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0389/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0389/html</guid>
    </item>
    <item>
      <title>Comprehensive analysis and clinical case studies on pseudoeosinophilia: insights and implications – unraveling the complexity: analytical approaches and clinical significance</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0249/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0249/html</guid>
    </item>
    <item>
      <title>Misdiagnosis of type 2B von Willebrand disease as immune thrombocytopenia in a thrombocytopenic patient</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2023-0891/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2023-0891/html</guid>
    </item>
    <item>
      <title>Biological matrices, reagents and turnaround-time: the full-circle of artificial intelligence in the pre-analytical Phase. Comment on Turcic A, et al., Machine learning to optimize cerebrospinal fluid dilution for analysis of MRZH reaction. CCLM 2024;62:436–41</title>
      <link>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0210/html</link>
      <guid>https://www.degruyter.com/document/doi/10.1515/cclm-2024-0210/html</guid>
    </item>
  </channel>
</rss>
